Wells Fargo & Company Ascendis Pharma A/S Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Wells Fargo & Company holds 10,610 shares of ASND stock, worth $1.56 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,610
Previous 11,061
4.08%
Holding current value
$1.56 Million
Previous $1.67 Million
13.52%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding ASND
# of Institutions
223Shares Held
56.5MCall Options Held
142KPut Options Held
259K-
Ra Capital Management, L.P. Boston, MA10.1MShares$1.48 Billion20.78% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.96MShares$728 Million3.41% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.3MShares$630 Million0.93% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.2MShares$615 Million7.81% of portfolio
-
Janus Henderson Group PLC London, X03.92MShares$574 Million0.29% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $8.18B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...